Lenz Robert A. 4

What Happened

• Robert A. Lenz, a director of LB Pharmaceuticals, was granted a derivative award covering 20,000 shares on 2026-03-06. The Form 4 lists the acquisition price as $0.00 (derivative interest), indicating no cash was paid at grant. This was an award/grant (code A), not a purchase or sale of stock.

Key Details

• Transaction date: 2026-03-06; Form 4 filed: 2026-03-10 (appears timely under the two-business-day rule).
• Transaction type/code: Award/Grant (A); reported as derivative interest with price $0.00.
• Shares reported: 20,000 underlying shares subject to the award. Shares owned following the transaction are not specified in this filing.
• Footnote: The shares subject to the option award vest in three equal annual installments on March 6, 2027, March 6, 2028 and March 6, 2029, subject to continuous service.
• No tax-withholding, sales, or exercise noted in this filing.

Context

• This filing documents a compensation-related derivative grant (option award) that vests over time — a common form of director pay. It is not an immediate cash purchase or sale and does not, by itself, indicate the insider is buying or selling shares in the open market.